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prediction models in this routine clinical validation 
population. 
Results: The C-index for the published prediction models was 
0.72, 0.75 and 0.72 in predicting 2-year local recurrence 
(LR), distant metastases (DM) and overall survival (OS) in the 
Chinese population, respectively. Kaplan-Meier curves 
indicated good discriminating performance of local control, 
however, couldn’t discriminate a low-risk and medium-risk 
group well for distant control and overall survival. Calibration 
curves showed a trend of underestimation of local and 
distant control, as well as overall survival in the observed 
data compared with the model predicted one. 
Conclusions: We externally validated three models for 
predicting 2-year LR, DM and OS of locally advanced rectal 
cancer patients who underwent preoperative chemoradiation 
and curative surgery with good discrimination in a single 
Chinese cohort, however the model overestimated the local 
control rate compared to observations in the clinical cohort. 
Furthermore, validation in other clinical routine cohorts and 
optimization of the prediction model including additional 
prognostic factors will enhance model validity and enhance 
applicability for personalized treatment of locally advanced 
rectal cancer. 
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Purpose/Objective: This study is to report initial clinical 
response of hepatocellular carcinoma (HCC) treated with 
dynamic tumor-tracking stereotactic body radiotherapy (DTT-
SBRT) with real-time monitoring using the Vero4DRT system. 
Materials and Methods: Eligibility criteria for this study were 
(1) one liver tumor with a diameter of 50mm or less, (2) 
technical difficulties for ablation therapies, inoperable, (3) 
performance status of 0-2, (4) Child-Pugh score of 8 or less, 
and (5) respiratory motion of 10mm or more. A fiducial 
marker (Visicoil) was placed near the tumor percutaneously 
under ultrasonographic guidance in advance. Internal target 
volume (ITV) for tracking was defined on the end-exhale 
phase of a 4DCT set. The ITV was delineated to compensate 
tumor-marker variation during respiration. Planning target 
volume (PTV) margin was defined for each patient taking 
some factors into account: interfraction variation of positions 
between the tumor and Visicoil, 4D modeling error, baseline 
drift of the abdominal wall movement, and mechanical error 
of the Vero4DRT. 
Between August 2013 and August 2014, nine patients were 
included in this study. Three were male and six were female. 
A median age was 79 years old with the range from 68 to 88. 
A median tumor diameter was 30 mm with the range from 8 
mm to 50 mm. In the Child-Pugh classification, five patients 
were classified to the Child-Pugh A, and others were 
classifies to B. Six patients were treated with 48 Gy in four 
fractions and others with tumor near digestive tract were 
treated with 56 Gy in eight fractions at isocenter by using 6-
MV photon beam. 
Results: DTT-SBRT was performed successfully. In contrast-
enhancement CT or MRI after 3 months or more from DTT-
SBRT, early arterial enhancement of HCC disappeared in 
eight patients. The other one had still early arterial 
enhancement in the tumor but this enhancement area was 
decreased at 45 days later from DTT-SBRT. All patients were 
classified to the same Child-Pugh criteria. No grade 2 or more 
adverse effect was noted. Two patients had a new HCC 
outside irradiation field. 
Conclusions: DTT-SBRT with real-time monitoring using 
Vero4DRT system seemed to be effective in the treatment of 
HCC. DTT-SBRT has the possibility of alternative method in 
the treatment of HCC. 
   
EP-1202   
Outcomes of adjuvant chemoradiotherapy following local 
excision for patients diagnosed as early rectal cancer 
N. Taek-Keun1, Y. Mee Sun1, S. Ju-Young1, A. Sung-Ja1, C. 
Woong-Ki1, K. Yong-Hyeob1, J. Jae-UK1 
1Chonnam Natioanl University Medical School, Radiation 
oncology, Kwangju, Korea Republic of  
 
Purpose/Objective: We evaluated the outcomes of adjuvant 
chemoradiotherapy (CRT) following local excision in patients 
diagnosed as early rectal cancer. 
Materials and Methods: Eighty five patients who had 
completed postoperative adjuvant CRT after local excision of 
early rectal cancer were included in this analysis. All patients 
were pathologically confirmed as stage T1 or stage T2 rectal 
cancer after local excision. The radiation dose ranged from 
39.6 Gy ~ 59.4 Gy (median; 50.4), given in 1.8 Gy fractions 
over 4 or 7 weeks. A concurrent chemotherapy regimen of 
fluorouracil (425 mg/m2/day) and leucovorin (20 mg/m2/day) 
was administered for 4 days during week 1 and 5 of 
radiotherapy except 2 patients (2.4 %) who refused 
chemotherapy. 
Results: Seventeen patients (20 %) showed pathologic stage 
T2 and 20 patients (23.5 %) showed resection margin of less 
than 3 mm. The median duration of follow-up was 49 months. 
The median survival was not reached. The 5-year overall 
survival, locoregional relapse-free survival, and disease-free 
survival rate for all 85 patients were 96.8 %, 92.3 %, and 91.3 
%, respectively. The patients with pathologic T2 stage (p = 
0.004) or resection margin < 3 mm (p = 0.006) showed worse 
disease-free survival in multivariate analysis. In thirty-four 
patients with pathologic T2 stage and/or resection margin < 3 
mm, four patients who received radiotherapy of 54.0 Gy did 
not develop any recurrence, while 3 out of 30 patients (10.0 
%) of equal or less than 50.4 Gy developed local failure. 
Conclusions: Postoperative CRT following local excision in 
patients with early rectal cancer could be effective adjuvant 
treatment without revision radical surgery. However, we 
recommend that radiotherapy dose of 54.0 Gy might be 
necessary to achieve better local control in the patients with 
pathologic T2 stage and/or resection margin < 3 mm.  
